What is Fluidic Sciences?
Founded in 2013 as a spin-out from the University of Cambridge, Fluidic Sciences specializes in the design, development, and manufacturing of innovative tools for the rapid and accurate characterization of proteins. The company operates at the intersection of deep-tech and life sciences, providing essential infrastructure for laboratory, medical, and consumer-facing diagnostics. By leveraging advanced microfluidic technology, the firm addresses critical bottlenecks in protein analysis, offering solutions that are both convenient and highly precise. Its market position is bolstered by its deep roots in the Cambridge academic ecosystem, allowing it to translate complex research into scalable, industry-ready products that serve a diverse range of scientific and commercial stakeholders.
How much funding has Fluidic Sciences raised?
Fluidic Sciences has raised a total of $40.3M across 3 funding rounds:
Series A
$2.4M
Series B
$6.9M
Unspecified
$31M
Series A (2015): $2.4M with participation from Parkwalk Advisors, DFJ Esprit, Amadeus Capital Partners, and Cambridge Enterprise
Series B (2016): $6.9M led by Cambridge Enterprise, IQ Capital Partners, Molten, Amadeus Capital Partners, Cambridge Innovation Capital, and Parkwalk Advisors
Unspecified (2018): $31M supported by Delin Ventures, IQ Capital, BGF, Molten, and Amadeus Capital Partners
Key Investors in Fluidic Sciences
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding, expertise, and networks.
IQ Capital
IQ Capital is a venture capital firm based in Cambridge and London that invests in deep-tech across sectors including machine learning, AI, and advanced engineering, with a focus on disruptive, globally scalable propositions.
Amadeus Capital Partners
Amadeus Capital Partners is a London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, and deep tech.
What's next for Fluidic Sciences?
Looking ahead, the strategic deployment of the $31M is expected to focus on scaling manufacturing capabilities and broadening the application scope of the company's core technology. As Fluidic Sciences transitions from a research-heavy spinout to a mature enterprise-level entity, the focus will likely shift toward global market penetration and the integration of its protein characterization tools into high-throughput clinical environments. The continued support from seasoned venture capital partners suggests a clear path toward long-term value creation, with potential milestones including the expansion of its intellectual property portfolio and the pursuit of strategic partnerships to enhance its diagnostic reach. The company remains a key indicator of the vitality of the UK's deep-tech sector, particularly in the application of disruptive algorithms and advanced engineering to biological challenges.
See full Fluidic Sciences company page
